Antiarrhythmics

Key Points

• Antiarrhythmics regulate cardiac conduction to control rate/rhythm or restore sinus rhythm.
• All antiarrhythmics carry proarrhythmic risk, so ECG and electrolyte monitoring are safety-critical.
• Class I (for example quinidine) can prolong QT and trigger torsades de pointes.
• Sotalol initiation requires facility-level QTc monitoring; dose changes are required when QTc is prolonged.
• Amiodarone has severe toxicity risk (pulmonary, hepatic, bradyarrhythmic/conduction toxicity) and requires close follow-up.
• Adenosine for PSVT is given as rapid IV bolus with saline flush; brief transient asystole may occur.

Pathophysiology

Arrhythmias include bradycardic, tachycardic, and irregular rhythms caused by altered impulse generation or conduction. Antiarrhythmics modify ion-channel flux and autonomic effects to suppress pathologic rhythms.

Because these agents alter conduction and refractoriness, they can also worsen rhythm instability. RN management requires focused pre-dose and post-dose surveillance of ECG pattern, blood pressure, heart rate, and electrolyte trends.

Classification

Class	Prototype Examples	Core Action
Class I Sodium Channel Blockers	quinidine, lidocaine, flecainide	Slow conduction and prolong depolarization by reducing sodium influx
Class II Beta-Blockers	sotalol (also Class III activity)	Reduce conduction velocity and automaticity; prolong refractory period
Class III Potassium Channel Blockers	amiodarone	Prolong repolarization by blocking potassium channels
Class IV Calcium Channel Blockers	diltiazem, verapamil	Slow AV-node calcium influx and ventricular response
Unclassified	adenosine	Transiently blocks AV-node conduction to terminate PSVT

Nursing Assessment

NCLEX Focus

Prioritize rhythm-safety monitoring: ECG trend, QT/QTc, electrolytes, perfusion, and contraindication screening before each dose decision.

• Assess baseline rhythm and hemodynamic status before administration.
• Monitor electrolytes relevant to proarrhythmia risk, especially potassium.
• For quinidine and related Class I use, monitor QT interval and thrombocytopenia risk.
• For sotalol initiation/titration, monitor QTc about 2-4 hours after each early dose and evaluate renal function for dose adjustment.
• For sotalol, treat QTc greater than about 500 msec as a dosing-safety escalation threshold per protocol.
• For amiodarone, assess hepatic, pulmonary, and conduction-risk factors and reconcile interacting medications.
• For diltiazem/verapamil pathways, assess for hypotension, AV block, bradycardia, and heart-failure worsening risk.
• For adenosine administration, prepare for transient conduction pause/asystole and continuous ECG response monitoring.

Nursing Interventions

• Use continuous or intermittent ECG monitoring based on medication phase and acuity.
• Hold/escalate when contraindication patterns are present (for example severe bradycardia, higher-grade block without pacing support, hypotension, severe bronchospasm risk where applicable).
• For adenosine PSVT treatment, place client supine and administer rapid IV bolus followed by saline flush per protocol.
• Reinforce adherence and avoid unsupervised dose doubling after missed doses.
• Teach pulse/BP self-monitoring parameters and urgent reporting for syncope, fast irregular pulse, or worsening dizziness.
• Teach orthostatic precautions and photosensitivity precautions where relevant.
• Counsel to avoid grapefruit and sour orange products with susceptible antiarrhythmic pathways.

Proarrhythmia Risk

Antiarrhythmics can worsen or induce dysrhythmia; initiation and dose changes require disciplined ECG-guided reassessment.

Nonlife-Threatening Arrhythmia Caution

In selected trials, antiarrhythmic use for nonlife-threatening arrhythmias increased mortality risk versus placebo.

Pharmacology

Drug	Typical Clinical Use	Key RN Considerations
Quinidine	Ventricular dysrhythmias; refractory AF conversion contexts	QT prolongation/torsades risk, thrombocytopenia surveillance, avoid grapefruit/sour orange, caution with HF/renal/hepatic dysfunction
Sotalol	Severe ventricular or supraventricular arrhythmias	Boxed arrhythmia risk, QTc checks 2-4 hours after initial doses, renal-dose adjustment, avoid in low potassium/bradycardia/high-grade block/HF/bronchospasm
Amiodarone	Life-threatening recurrent ventricular arrhythmias refractory/intolerant to alternatives	Fatal-toxicity risk (pulmonary/hepatic/conduction), hospitalization commonly needed for initiation/loading, interaction review and close follow-up
Diltiazem (Class IV antiarrhythmic use)	SVT rate control; also angina/HTN contexts	Monitor bradycardia/hypotension/AV block/HF worsening, avoid in hypotension or acute MI/high-grade block/sick sinus without pacing
Adenosine	Paroxysmal supraventricular tachycardia termination	Rapid IV push + flush, transient brief asystole may occur, monitor for hypotension/bronchospasm/severe discomfort/arrhythmia recurrence

Clinical Judgment Application

Clinical Scenario

A client with persistent tachyarrhythmia is newly started on sotalol during monitored inpatient initiation.

• Recognize Cues: Baseline rhythm instability, renal-function dependence, and QTc-sensitive medication profile.
• Analyze Cues: Early-dose period carries elevated proarrhythmia risk if QTc prolongs.
• Prioritize Hypotheses: Highest priority is drug-induced dysrhythmia prevention while achieving rhythm control.
• Generate Solutions: Schedule protocol ECG/QTc checks, electrolyte surveillance, and dose-adjustment readiness.
• Take Action: Administer as ordered with timed reassessment and immediate escalation for QTc or perfusion deterioration.
• Evaluate Outcomes: Rhythm control improves without torsades, severe bradycardia, or hemodynamic decline.

Related Concepts

• systematic-ecg-interpretation-and-dysrhythmia-triage - ECG interpretation and emergency rhythm triage framework.
• beta-blockers - Class II overlap and bradycardia/hypotension monitoring.
• calcium-channel-blockers - Class IV overlap for AV-node rate control.
• heart-failure - Comorbid HF increases antiarrhythmic risk complexity.
• anticoagulants - Common co-therapy in atrial-fibrillation pathways.

Self-Check

1. Why must antiarrhythmic therapy decisions be linked to ECG and electrolyte trends?
2. Which safety checks are priority during sotalol initiation?
3. What bedside event is expected briefly after adenosine rapid IV administration?